

Treatment Advice Letter

Patient's Details:

Attach patient identification Sticker
Title: _____
First name: _____
Surname: _____
Patient's Address: _____

D.o.b: _____

GP's Details:

Name: _____

Practice: _____

Known Allergies: _____

Date: _____

Dear Dr.

Your patient has been assessed at the Sheffield Pulmonary Vascular Disease Unit for Pulmonary Hypertension and been prescribed Bosentan ▼ tablets (Tracleer®) 62.5mg twice a day for one month then increasing to 125mg twice a day thereafter.

Bosentan ▼ is an Endothelin Receptor Antagonist. It exerts its' beneficial reduction in pulmonary artery pressure by endothelin blockade; inhibiting further pulmonary vasoconstriction and reducing smooth muscle proliferation. Bosentan ▼ is licensed to treat PAH and is endorsed by the UK National Commissioning Policy.

The treatment has already been initiated. Written information on how to take the tablets has been provided and counselling given at the hospital. Bosentan has several drug-drug interactions (e.g. warfarin) as a result of CP450 enzyme induction. Please refer to the Summary of Product Characteristics (SPC) for detailed information on management of these interactions and potential undesirable effects before prescribing other medications to your patient.

In accordance with the product license, the patient needs to have regular blood tests (Full Liver Function Test screen monthly, Full Blood Count quarterly and monthly pregnancy blood test for ladies of child-bearing potential). The patient will be in touch with the surgery to arrange the blood sampling, but will be supplied with vacutainers, lab request forms and pre-paid envelopes to send the blood to us for analysis.

This medication is funded by NHS England and is prescribed by the Sheffield Pulmonary Vascular Disease Unit. You should not be asked for prescriptions for this medication as the patient will be delivered all supplies and ancillaries by our Homecare Partners, Healthcare at Home (0870 600 1540) or BUPA Home Healthcare (0845 8888 235). You are advised where possible, to insert this drug onto GP repeat prescribing systems so as to highlight any potentially harmful drug interactions. There is a useful reminder on how to do this for GP practices on the [intranet](#).

If you have any queries regarding this or any aspect of their treatment, please do not hesitate to contact me on 0114 271 3259 or neil.hamilton@nhs.net.

Yours Faithfully



Neil Hamilton,
Pulmonary Vascular Disease Unit Pharmacist